Compare Stryker Corporation (SYK) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Stryker Corporation trades at $319.04 (market cap $122.35B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.71. The key difference: Stryker Corporation pays a 1% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Stryker Corporation nearer its low. Which is the better fit depends on your goals.
| SYK | VEA | |
|---|---|---|
Market Cap | $122.35B | — |
Sector | Technology | — |
52-Week High | $403.53 | $72.39 |
52-Week Low | $282.58 | $56.02 |
Enterprise Value | $134.10B | — |
Dividend Yield | 1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $319.14, down 0.23% with a bearish technical signal despite strong fundamentals. The company reported $25.12B revenue and $3.25B net income for 2025, maintaining robust margins. Recent news highlights Mako RPS launch expansion in robotic surgery, while Q1 2026 earnings missed expectations due to a temporary cyber disruption, though full-year guidance remains unchanged.
Outlook remains positive with 74% analyst buy ratings and a $388.44 consensus price target implying 22% upside. Key risks include competitive pressures and execution challenges from recent cybersecurity issues. The stock presents a growth opportunity in med-tech innovation, trading below historical valuation multiples with healthy cash flow generation.
VEA trades at $69.23, down 0.67% today, with technical indicators showing a bearish trend. The ETF's moving averages signal selling pressure, while oscillators remain neutral. Recent news highlights strong 2026 performance against U.S. benchmarks and institutional buying interest. Vanguard's low 0.03% expense ratio and focus on developed ex-U.S. markets provide cost-efficient diversification.
Outlook is mixed: technical weakness contrasts with fundamental appeal via valuation discounts to U.S. stocks. Risks include developed market central bank tightening and political volatility. Analysts note long-term outperformance potential, but near-term sentiment is cautious amid bearish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
